The Right model for your R&D program.
Create your advanced gene-edited
mouse and rat model.

Ask our experts

What is Fast-Track® Design?

JC Discovery® offers end-to-end services for the creation, maintenance and cryopreservation of Genetically Engineered rodent Models (GEMs mouse and rat lines), encompassing in vitro cell culture and in vivo preclinical models.

A large range of models also available that can be immunoprofiled with Fast-Track® Immunomics.

Discuss my project

Generate gene customised models

JC Discovery® technologies include ES cell based and CRISPR-Cas9 genome editing introducing knock-in and knock–out mutation.s, point mutation, adding new functionality (human orthologues), multi-task allels.

We own licenses on all technologies used to develop your model (CRISPR-Cas9 license) allowing you to retain ownership of your proprietary models.

Advanced gene-edited in vitro cell preclinical models 

Fast-TrackTM Gene editing covers wide range of: 

  • Customised mice and human cell lines
  • PDX-Derived Cells (PDX-DCs)
  • Therapeutic T and CAR-T cells
Customised mouse and human cell lines

For decades, the field of oncology has relied on the utilization of both mice and human cancer cell lines to identify effective anti-cancer drugs.
As they have been widely used in drug development, they are still considered as a robust tool for rapid compound screening.

The use of idnetical cell lines allows for a direct transition from in vitro compound selection to in vivo studies. Following the in vitro selection of hit compounds, a seamless transition to in vivo studies is possible by using the same cell lines.

In this context, JC Discovery® and XenTech provide a flexibility to test compounds as single agents or in combinations. We offer guidance on selecting the most relevant modelfor your project or accomodate your preferred choice.

See more
PDX-derived cells (PDX-DCs)

PDX in vivo systems are now widely used for screening during discovery development. We developed a panel of PDX-derived cell lines (PDX-DCs) for time and cost-effective medium-throughput screening to profile the anti-cancer efficacy of early test compound development. To date, 40+ PDX-DCs from various indications such as breast, lung, prostate, and many others have been generated.

This panel is offered at our facilities to allow further validation in the parental PDX models in vivo.

These models enable co-culture assays with immunes cells (PBMC, L-T, CAR-T) to evaluate immune-based therapies in vitro with Fast-Track® Immunomics.

For targeted therapies (CAR-T, ADC, PDC) antigen expression can be assessed by cytometry analysis before in vitro efficacy evaluation of drug candidates. 

Not all of our PDX are derived as cellular model, so if you are interested by a specific PDX, we can derive the cellular model on demand.

Our experts are ready to guide you in selecting the optimal model for your drug development.

See more
Therapeutic T and CAR-T cells

The Fast-Track® T-Cell platform is based on a long experience.
We aim at accelerating the selection of lead T-cell products and models for clinical translation by:
• Gene-editing and engineering of therapeutic T-cells
• Developing genetically enhanced CAR-T cells with improved effector functions and durability

Advanced gene-edited in vivo preclinical models - mice and rats (GEMs)

We specialize in designing mouse models utilizing primarily C57BL/6N ES cells, delivering them in a SOPF status. We own licences and all technologies used to develop your model. This allows you to retain ownership of your proprietary models.

Gene inactivation (KO) to delete-and-Track critical insights

Discovering gene functions represents a key stage in the basic understanding of functional genomics, disease pathogenesis, and new therapy development.

We offer:

  • Straight knock out (constitutive knockout)
  • Conditional knock-out (floxed allels)
  • Tissue-specific expression of iCre
  • Tissue-specific expression of creERT2 or MerCre-Mer

These models allow:

  • Gene study
  • Target validation
  • Compound specificity/toxicity studies
Gene Mutation or Replacement (KI) to add-and-track Critical insights

JC Discovery® enables to gain insights into the mechanisms of immune responses in the context of inflammation, infections, and tumor biology.

Addressing most challenging projects, CIPHE has developed a unique expertise in knock-in mouse whether it consists in inserting a reporter to track gene expression or adding a new functionality (human orthologues).

These models allow:

  • Reporting gene expression 
  • Cell/protein trafficking 
  • Genetic cell ablation in vivo  
  • Interactomics and signalosomics 
  • Multianalytic alleles

We offer:

  • Fluorescent reporter (EGFP, TdTomato, Teal) in the 3’UTR of a gene of interest under the control of an IRES
  • Human DTR cassette in the 3’ UTR of a gene of interest under the control of an IRES
  • One Strep Tag in the 3’UTR of a gene of interest
  • Multitask cassettes IRES (Fluorescent reporter) - T2A human DTR

Discover our ready-to-use models

A wide range of ready-to-use models for your preclinical testing programs.

You may also be interested in...


Characterise your models (immunoprofiling) and access knowledge with gold-standard immunomics.


Fast colony expansion and preservation for your preclinical trials.


Your models delivered directly to your facilities with dedicated transport.

Frequently asked questions

What's the timeline for model generation?

The estimated timeline depends on the desired genetic modification, careful evaluation of the target gene locus and technology used, CRISPR-Cas9 or homologous recombination. From project initiation to F1 generation and genetic validation, it takes between 16 and 44 weeks. We take care of securing your strain before ensuring the customized breeding providing you with strandardized cohorts and supporting your research projects within the competitive timeframe.

Can I make a model with complex multitask alleles?

Our team of mouse geneticists has a longstanding experience and will guide you to carefully evaluate the feasibility of the desired gene editing to achieve complex multitask alleles.

What is the technical and economical feasibility for the creation of my model?

A dedicated team of mouse geneticists experts will work with you to design a model that will technically achieve your research needs and economical options. They use wide variety of model generation technologies and can advise on which strategies will minimize risk. It will take 2 weeks in average depending on the complexity of the model to be designed.

Do I have an intellectual property of model I order?

Regardless of the technique used to create your model, by homologous recombination or by CRISPR-Cas9 gene editing, the newly created model belongs to you. The model characterization data provided by our experts at JC Discovery® are also covered by our intellectual proprietary rights.